GlassScriptPhysician profile
Emilio Juncosa
NPI 1568485969
$1,508.38
in general payments reported to CMS, 2019-2025
17 companies · $30.09 in 2025
The $30.09 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $368 · 2021: $449 · 2022: $80.32 · 2023: $208 · 2024: $43.34 · 2025: $30.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.21 | 2019-2021 | |
| Astellas Pharma US INC | $234.32 | 2022-2025 | Veozah |
| Organogenesis INC. | $153.98 | 2020 | |
| Aspira Women'S Health INC | $99.18 | 2020 | |
| Coopersurgical, INC. | $96.88 | 2020-2025 | Endosee, Paragard T 380a |
| Hologic Sales and Service, LLC | $59.31 | 2020-2024 | Aptima |
| Roche Diagnostics Corporation | $55.63 | 2019-2021 | |
| Evofem Biosciences, INC. | $46.79 | 2021 | |
| Lupin INC. | $40.66 | 2019-2020 | |
| Therapeuticsmd, INC. | $39.36 | 2019-2020 | |
| Pfizer INC. | $37.59 | 2019 | |
| Mayne Pharma Commercial LLC | $36.90 | 2021-2022 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Allergan, INC. | $15.22 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.50 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $13.01 | 2019 | |
| Avion Pharmaceuticals | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilio Juncosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.